Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

BACKGROUND: Pharmacogenetic (PGx) testing identifies pharmacotherapeutic risks to permit personalized therapy. Identifying the genetic profile of patients with acute coronary syndrome (ACS) who are considered for therapy with clopidogrel (P2Y(12) receptor blockers) and acetylsalicylic acid (ASA) con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clinicoecon Outcomes Res
Main Authors: Bereza, Basil G, Coyle, Doug, So, Derek Y, Kadziola, Zbigniew, Wells, George, Grootendorst, Paul, Papadimitropoulos, Emmanuel A
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7090184/
https://ncbi.nlm.nih.gov/pubmed/32256091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S234298
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados